New trick for old drug; Vascepa cost effective for CV reduction

Friday, December 6, 2019

Icosapent ethyl cost effective in REDUCE-IT analysis
Treatment with the fish-derived drug Vascepa for CV event reduction is more effective and less costly than placebo.

* * *

Help us make this podcast better! Please take our short listener survey:

* * *

DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
The SGLT2 inhibitor had similar efficacy in the elderly and across the spectrum of baseline symptom status.

Colchicine cut post-MI CVD events
Colchicine fulfilled the promise first seen in CANTOS that anti-inflammatory treatment can reduce cardiovascular disease events.

Cardiac arrests peak with pollution in Japan
The incidence of out-of-hospital cardiac arrests in Japan increased on days when counts of particulate matter spiked from the day before.

* * *

For more MDedge Podcasts, go to

Email the show:

Interact with us on Twitter: @MDedgeTweets

Podcast Participants

Jim Dwyer, MD
Jim Dwyer MD, FACC, FSCAI, is a cardiologist and avid horseman in Prescott, Ariz. Trained at Saint Louis University, he spent more than 30 years in interventional cardiology. He recently hung up his lead apron and has joined a private cardiology practice. Dr. Dwyer has been producing health segments for radio broadcast for 20 years. He has no disclosures.